Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Outcomes for patients with acute myeloid leukemia (AML) have improved due to advances in therapeutic approaches in combination with improvements in supportive care. However, relapse remains a significant clinical challenge and research has focused on maintenance strategies to extend remission and overall survival in patients with AML.1
Andrew Wei, MBBS, PhD
Alfred Hospital and Monash University, Melbourne, Australia
Simona Pagliuca, MD, PhD
Nancy University Hospital, Nancy, France
Andrius Žučenka, MD
Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
Felicitas Thol, MD
Hannover Medical School, Hannover, Germany
Marina Konopleva, MD, PhD
Albert Einstein College of Medicine, New York City, NY
Ali Bazarbachi, MD, PhD
American University of Beirut, Beirut, Lebanon
Steven Knapper, DM, FRCPath, MRCP, BMBCh
Cardiff University, Cardiff, Wales, UK
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Claudio Cerchione, MD, PhD
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
Musa Yilmaz, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Paresh Vyas, MRCP, FRCP, FRCPath
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Arnon Nagler, MD
Chaim Sheba Medical Center, Tel-Aviv, Israel
Jacqueline Garcia, MD
Dana-Farber Cancer Institute, Boston, MA
Marina Konopleva, MD, PhD
Albert Einstein College of Medicine, New York City, NY
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Aaron Goldberg, MD, PhD
Memorial Sloan-Kettering Cancer Center, New York, NY
Ibrahim Aldoss, MD
City of Hope, Duarte, CA
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Keri Maher, DO
VCU Health, Richmond, VA
Christoph Röllig, MD, MSc
Dresden University of Technology, Dresden, Germany
Mark Litzow, MD
Mayo Clinic, Rochester, MN
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, Birmingham, UK
Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Keri Maher, DO
VCU Health, Richmond, VA
Nicholas Short, MD
MD Anderson Cancer Center, Houston, TX
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK
Thomas Cluzeau, MD, PhD
University Hospital of Nice, Nice, France
Marion Subklewe, MD
Ludwig-Maximilians-University of Munich, Munich, Germany
Amir Fathi, MD, MPH
Massachusetts General Hospital, Boston, MA
Thomas Cluzeau, MD, PhD
University Hospital of Nice, Nice, France
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Alessandro Isidori, MD, PhD
Marche Nord Hospital, Pesaro, Italy
Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD
King’s College Hospital NHS Foundation Trust, London, UK
Reference:
1. Reville, P.K. and Kadia, T.M. Maintenance therapy in AML. Frontiers in Oncology 2021;10:619085. doi:10.3389/fonc.2020.619085.
5:18
Glossary
AML, acute myeloid leukemia
This educational activity has received independent medical education support from Bristol Myers Squibb. This supporter has no influence over the production of the content.